Modeling Effects of SGLT‐2 Inhibitor Dapagliflozin Treatment vs. Standard Diabetes Therapy on Cardiovascular and Microvascular Outcomes

ConclusionsBased on these simulation results, adding dapagliflozin to currently available treatment options is projected to further decrease the CV and microvascular complications associated with T2DM.

Source: Diabetes, Obesity and Metabolism - January 20, 2014 Category: Endocrinology Authors: J. Dziuba, P. Alperin, J. Racketa, U. Iloeje, D. Goswami, E. Hardy, I. Perlstein, H.L. Grossman, M. Cohen Tags: Original Paper Source Type: research